Mechanical heart valves and Anticoagulation. Dr. Alkesh ZALA Basic Physician trainee, Dept. of Cardiology, John Hunter hospital.
|
|
- Nelson Cain
- 5 years ago
- Views:
Transcription
1 Mechanical heart valves and Anticoagulation Dr. Alkesh ZALA Basic Physician trainee, Dept. of Cardiology, John Hunter hospital.
2 Today s discussion: Case review The currently Available and most commonly Used mechanical prostheses. What determines the Choice of valves? Risk of Valve Thrombosis WITHOUT Anticoagulation What are the INR Targets for these valves? Are the New Generation Valves Really LESS THORMBOGENIC?
3
4 CASE 75 year old lady with subdural bleed On warfarin for st. Jude s bileaflet AVR alond with Bentall procedure in Embolic vertebrobassilar embolic stroke Valve blammed THOUGH INR 3.2 Aspirin added and INR target now INR within target range on presentation Surgical drainage on presentation day 4 Heparin infusion on day 5 & Warfarin recommenced on regular dose on day 7 TOO EARLY?
5 Day 9 increasingly confused with headache. Repeat CT Acute subdural with midline shift Urgent surgical drainage Repeat CT on day13 subdural stable. No focal Neurological deficit Heparin started Cardiology involved with regards to anticoagulation advise Summary: Elderly lady with st.jude s bileafletvalve along with Bentall sprocedure. Prior probable embolic stroke related to the Mechanical valve Risk of valve thrombosis Vs Serious risk of intracranial bleeding
6 Weighing the risk of valve thormbosis and serious significant risk of recurrence of the intracranial bleed: - Go OFF anticoagulation for 1-2 weeks. - Warfarin restarted next week Uneventful recovery without any further complications. Gamble -Turns Out To Be a Winner Or A rational evidence based decision
7 An ideal Prosthetic valve Unidirectional flow Durable : 40million cycles/year Blood compatible: no thrombus, embolus Central flow: Laminar not turbulent Closing not damaging blood cells Last but not the least important It should be quiet
8 Evolution of Prosthetic Heart Valves The development of the original balland-cage valve design can be attributed to the bottle stopper in 1858 In the early 1950 s, it led to the idea of a prosthetic heart valve consisting of a cage with a mobile spherical poppet First implanted in a human in a closed procedure in September of In 1953, marked successful use of the heart and lung machine, paving the way for the 1 st open heart operations
9 Early valves In the 1960s, the Starr Edwards ball-and-cage mechanical prosthesis became the standard replacement valve for nearly a decade. The tilting disc valve became more widely used in the 1970s to overcome some of the inherent problems of the ball-and-cage model. Both of these designs, however, were plagued by hemodynamic limitations and thromboembolic complications. In the 1980s, the St. Jude Medical bileaflet prosthesis supplanted the earlier devices as the most commonly implanted prosthetic heart valve. Since then, additional bileaflet devices with numerous design modifications have been developed and continue to be used today.
10 Different types of prosthetic valves. A, Bileaflet mechanical valve (St. Jude Medical). B, Monoleaflet mechanical valve (Medtronic- Hall). C,Caged ball valve (Starr-Edwards,). D,Stented porcine bioprosthesis (Medtronic Mosaic). E,Stented pericardial bioprosthesis (Carpentier-Edwards Magna). F,Stentless porcine bioprosthesis (Medtronic Freestyle). G,Transcatheter bioprosthesis expanded over a balloon (Edwards SAPIEN). H, Self-expandable percutaneous bioprosthesis (CoreValve,)edtronic).
11 Bileaflet valves Two semicircular leaflets that rotate about struts attached to the valve housing Good hemodynamic performance -improved flow characteristics, lower transvalvular pressure gradients, less blood flow turbulence, improved hemodynamics at a given annular diameter, a larger orifice area and low bulk and flat profile the least thrombogenic of the artificial valves most commonly implanted mechanical valves
12 FDA-approved prosthetic heart valves
13 Haemodynamics of blood flow
14 However, inspiteof improved design and haemodynamics still haunted by numerous complications and the most dreaded one of valve thrombosis
15 Why not always use a Bioprosthetic valve!! Developed primarily to overcome the risk of thromboembolism that is inherent in all mechanical prosthetic valves Major problem DURABILITY. Cuspal tears, degeneration, fibrin deposition, perforation, fibrosis, and calcification. Rate of tissue failure by 10 years 30% and upto 60% by 15 years.
16
17 Choice of Valves Major task is to weigh the advantage of durability and the disadvantages of the risks of thromboembolism and anticoagulant treatment inherent with mechanical valves The next step is to choose a prosthesis model that provides superior hemodynamic performance to prevent prosthesis-patient mismatch (PPM) and thereby minimize postoperative trans-prosthetic gradients.
18 Criteria for selection of an aortic valve in patients undergoing aortic valve replacement (AVR) ACC/AHA guideline Class I -There is evidence and/or general agreement for the choice of a mechanical or bioprosthetic valve in patients undergoing AVR in the following settings A mechanical valve in patients who already have a mechanical valve in the mitral or tricuspid position. A bioprostheticvalve in patients who will not take or are incapable of taking warfarin or have a major contraindication to warfarin therapy. Class IIa - The weight of evidence or opinion is in favorof the choice of a mechanical or bioprosthetic valve in patients undergoing AVR in the following settings A bioprosthesisin patients 65 years of age who do not have risk factors for thromboembolism. Patient preference can be considered in patients less than 65 years of age: 1. A mechanical valve is reasonable in patients who do not have a contraindication to warfarin therapy. 2. A bioprostheticvalve may be chosen after a detailed discussion of the risks of warfarin therapy compared to the likelihood of repeat valve replacement in the future. A homograft when aortic valve re-replacement is performed for active prosthetic valve endocarditis. Class IIb - The weight of evidence or opinion is less well established for the choice of a mechanical or bioprosthetic valve in patients undergoing AVR in the following setting A bioprosthesis in women of child-bearing age to avoid the problems associated anticoagulation during pregnancy. Data from Bonow, RO, Carabello, BA, Chatterjee, K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for thamerican College of Cardiology/American Heart Association Task e management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.
19 Criteria for selection of an Mitral valve in patients undergoing Mitral valve replacement (MVR) ACC/AHA guideline Class I -There is evidence and/or general agreement for the choice of a mechanical or bioprosthetic valve in patients undergoing MVR in the following settings A bioprostheticvalve in patients who will not take or are incapable of taking warfarin or have a major contraindication to warfarin therapy. Class IIa - The weight of evidence or opinion is in favorof the choice of a mechanical or bioprostheticvalve in patients undergoing MVR in the following settings A bioprosthesisin patients 65 years of age who do not have risk factors for thromboembolism. Among patients < 65 years of age 1. Mechanical valve in patients with long standing Atrial fibrillation 2. A bioprosthetic valve may be chosen in patients in sinus rhythm who elect this for lifestyle considerations after a detailed discussion of the risks of warfarin therapy compared to the likelihood of repeat MVR in the future Data from Bonow, RO, Carabello, BA, Chatterjee, K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for thamerican College of Cardiology/American Heart Association Task e management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.
20 Patient tailored prosthesis
21 JHH Choice Mechanical valves represent about 5 10% of total valve replacement? Reason Preferred mechanical valve Bileafletvalve Mechanical valves Mitral > Aortic (However, Repair preferred over Replacement) Apart from co-morbidities and Patient preference AVR-Age 60 MVR Age 70 Courtesy: Dr. Taranpreet Singh Cardiothoracic surgeon, John Hunter Hospital
22 Thrombosis with Mechanical valve Mechanical prostheses remains burdened with the risk of thrombosis potentially fatal Valve thrombosis is any thrombus in the absence of infection attached to or near an operated valve that occludes part of the blood flow path or that interferes with the function of the valve. Risk factors: inadequate or discontinued anticoagulant therapy previous endocarditis the prosthetic valve model used LV dysfunction, LA dilatation Hypercoagulable states
23 Prosthesis Thrombogenicity Low: St Jude Medical, On-X, Carbomedics, Medtronic Hall; Medium: bileaflet valves with insufficient data, Bjork- Shiley; High: Lillehei-Kaster, Omniscience, Starr-Edwards. Philippe Pibarot, P. et al, Selection of the Optimal Prosthesis and Long-Term Management. Circulation. 2009; 119:
24 Rate of thrombosis In absence of anticoagulation: 8.6 per 100 patientyears. With anticoagulation: risk is reduced to 1% to 3% per year. Valve thrombosis is increased with valves in the mitral position. Highest in the Tricuspid position.?? Rate with remote valves Ref: Hurst's the Heart, 12th Edition
25 ACC/AHA guideline summary: Treatment of prosthetic heart valve thrombosis Class IIa - The weight of evidence or opinion is in favorof the usefulness of the following modalities in patients with prosthetic heart valve thrombosis Emergency surgery for thrombosis in a left-sided prosthetic heart valve in patients with New York Heart Association (NYHA) class III-IV symptoms. Emergency surgery for thrombosis in a left-sided prosthetic heart valve with a large clot burden. Fibrinolytic therapy for thrombosis in a right-sided prosthetic heart valve in patients with New York Heart Association (NYHA) class III-IV symptoms and/or a large clot burden. Class IIb - The weight of evidence or opinion is less well established for the usefulness of the following modalities in patients with prosthetic heart valve thrombosis Fibrinolytic therapy as a first-line approach for thrombosis in a left-sided prosthetic heart valve in patients with NYHA class I-II symptoms and a small clot burden. If surgery is either high risk or not available: 1. Fibrinolytic therapy as a first-line approach for thrombosis in a left-sided prosthetic heart valve in patients with NYHA class III-IV symptoms and a small clot burden. 2. Fibrinolytic therapy in patients with an obstructed, thrombosed left-sided prosthetic heart valve, class II-IV symptoms and, a large clot burden. Unfractionated heparin as an alternative to fibrinolytic therapy in patients with NYHA class I-II symptoms and a small clot burden. Bonow, RO, Carabello, BA, Chatterjee, K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1.
26
27 Anticoagulation guidelines ACC/AHA guideline summary: Antithrombotic therapy in patients with mechanical heart valves Class I -There is evidence and/or general agreement that antithrombotic therapy is indicated in patients with mechanical heart valves in the following settings: Warfarin to achieve a goal INR of 2.0 to 3.0 after: 1. Aortic valve replacement (AVR) with bileaflet mechanical or Medtronic Hall valves if no risk factors* are present. Warfarin to achieve a goal INR of 2.5 to 3.5 after: 1. AVR with bileafletmechanical or Medtronic Hall valves if risk factors* are present. 2. AVR with Starr-Edwards or disc valves other than Medtronic Hall if no risk factors* are present. 3. Mitral valve replacement (MVR) with any mechanical valve. Role of aspirin: 1. After AVR or MVR in patients who cannot take warfarin, at a dose of 75 to 325 mg/day. 2. At a dose of 75 to 100 mg/day in addition to warfarin in all patients with mechanical valves and in patients with biological valves who have risk factors*. Class IIa-The weight of evidence or opinion is in favorof the usefulness of antithrombotic therapy in patients with mechanical heart valves in the following setting: In the first three months after AVR, warfarin to achieve a goal INR of 2.5 to 3.5. Class IIb -The weight of evidence or opinion is less well established for the usefulness of antithrombotic therapy in patients with mechanical heart valves in the following setting: In high-risk patients in whom aspirin cannot be used, clopidogrel(75 mg/day) or warfarin to attain a goal INR of 3.5 to 4.5. Bonow RO, Carabello BA, Chatterjee K, et al Focused update incorporated into the ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). Circulation 2008; 118:e523.
28 European College of Cardiology guideline General principles Thromboembolic risk is related to two factors: Thrombogenicity of the mechanical valve 1. Low - Medtronic Hall, St Jude Medical (without Silzone), CarboMedics AVR 2. Medium - Bileaflet valves with insufficient data, Bjork-Shiley 3. High - Lillehei Kaster, Omniscience, Starr Edwards Presence or absence of risk factors: atrial fibrillation, left atrial dimension >50 mm, mitral valve gradient, left ventricular ejection fraction <35 percent, spontaneous echo contrast, mitral, tricuspid, or pulmonary valve replacement, or a hypercoagulable state. Recommendations for anticoagulation Until the INR is stable, intravenous unfractionated heparin (to achieve an activated partial thromboplastin time of 1.5 to 2.0) is probably safer than subcutaneous unfractionated heparin or low molecular weight heparin which, is used, should be accompanied by anti-factor XA monitoring, particularly in patients with renal failure or obesity. For low thrombogenicity valves, warfarin (or other vitamin K antagonist) to achieve a goal INR of 2.5 if no risk factors and 3.0 if risk factors. For medium thrombogenicity valves, warfarin (or other vitamin K antagonist) to achieve a goal INR of 3.0 if no risk factors and 3.5 if risk factors. For high thrombogenicity valves, warfarin (or other vitamin K antagonist) to achieve a goal INR of 3.5 if no risk factors and 4.0 if risk factors. Addition of antiplatelet therapy Relative indications 1. Concurrent arterial disease 2. Coronary artery stenting 3. Recurrent embolism, but only after treatment of risk factors and optimization of anticoagulation fail to abolish the problem With caged ball valves, with dipyridamole being preferred to aspirin Relative contraindications 1. History of gastrointestinal bleeding, particularly associated with ulcer disease or angiodysplasia. 2. Hyperrespondersto aspirin, with excessively prolonged bleeding time. 3. Poorly controlled hypertension, because of the risk of intracerebral hemorrhage. 4. Elderly patients, particularly women over age Patients who take multiple medications, require frequent courses of antibiotics, or have erratic INR control. Butchart, EG, Gohlke-Barwolf, C, Antunes, MJ, et al. Recommendations for the management of patients after heart valve surgery. Eur Heart J 2005; 26:2463.
29 The AREVA trial compared moderate anticoagulation (INR ) to the usual regimen of INR A similar risk in thromboembolic events was found in both arms, whereas the bleeding risk was higher in the high intensity group Acar J, Iung B, Boissel JP et al. AREVA. Multicenter randomized trial comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996; 94:
30 International Normalized Ratio (INR) specific incidence of all adverse events in patients with mechanical valves (all episodes of thromboembolism, all major bleeding episodes, and unclassified stroke) according to INR (A). The dotted lines represent the 95% confidence interval and according to INR, age, and position of valve (B). Incidence of thromboembolic events according to INR and patient age (upper graph) or prosthesis position (lower graph). S.C. Cannegieter, F.R. Rosendaal, A.R. Wintzen, F.J.M. van der Meer, J.P. Vandenbroucke, and E. Briet N Engl J Med 1995; 333:11-17July 6, 1995
31 LOWERING-IT trial established that the proposed LOW-INR target is safe and feasible in low-risk patients after bileaflet aortic mechanical valve replacement. prospective open-label, single-center, randomized controlled trial: age 20 to 60 years, a single-valve replacement with a bileafletvalve in the aortic position Low risk 396 patients: 197 in low INR ( ) AND 199 in standard INR group ( ). Results -similar thrombotic events and a significant reduction of bleeding occurrence in the low INR group Torella, M. Torella, D. LOWERing the INtensity of oral anticoagulant Therapy in patients with bileaf let mechanical aortic valve replacement: Results from the LOWERING-IT Trial. American heart Journal Volume 160, Issue 1 (July 2010)
32
33 Are new generation valves really less thrombogenic? All Mechanical valves models are vulnerable to thrombus formation due to high shear stress, stagnation, and flow separation. The quest to find a less thormbogenicvalve was one of the prime driving force in the development of the newer heart valves Less thrombogenicmaterials and an improved valve and hinge design has reduced the propensity for thrombus formation and the need for aggressive anticoagulation.
34 A meta-analysis of 46 trial -a higher risk of embolic complications in patients with a caged-ball valve. The incidence of total thromboembolism was 30% lower for patients with a tilting disk valve, and 50% lower for patients with a bileaflet valve. Cannegieter SC, Rosendaal FR, Torn M. Oral anticoagulant treatment in patients with mechanical heart valves: how to reduce the risk of thromboembolic and bleeding complications. Journal of Internal Medicine,Volume 245, Issue 4, pages , April 1999
35 In the cohort study of 1608 patients with mechanical heart valves: a clearly higher risk of thromboembolism in patients with caged-ball valves. An incidence of 0.5 per 100 patient-years was found for the bileaflet valves, of 0.7 per 100 patient-years for the tilting disk valves, and of 2.5 per 100 patient-years for the caged-ball valves Cannegieter SC, Rosendaal FR, Wintzen AR, Van Der Meer Fjm, Vandenbroucke JP, Briët E. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N Engl J Med 1995; 333:
36 Guideline Which valves are less thormobogenic and safe to be managed with lower INR targets??
37 The quest continues Eight Commandments : Embolism Prevention Durability Ease and Security of Attachment Preservation of Surrounding Tissue Function Reduction of Turbulance Reduction of Blood Trauma Reduction of Noise Use of Materials Compatible with Blood
38 References AcarJ, Iung B, BoisselJP et al. AREVA. Multicenterrandomized trial comparison of low-dose versus standard-dose anticoagulation in patients with mechanical prosthetic heart valves. Circulation 1996; 94: Bonow, RO, Carabello, BA, Chatterjee, K, et al. ACC/AHA 2006 guidelines for the management of patients with valvular heart disease. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing committee to revise the 1998 guidelines for the management of patients with valvular heart disease). J Am Coll Cardiol 2006; 48:e1. Braunwald's Heart Disease - A Textbook of Cardiovascular Medicine, 9th ed. CannegieterSC, RosendaalFR, WintzenAR, Van Der Meer Fjm, VandenbrouckeJP, BriëtE. Optimal oral anticoagulant therapy in patients with mechanical heart valves. N EnglJ Med 1995; 333: Hurst's the Heart, 12th Edition Torella, M. Torella, D. LOWERing the INtensityof oral anticoagulanttherapy in patients with bileafletmechanical aortic valve replacement: Results from the LOWERING-IT Trial. American heart Journal Volume 160, Issue 1 (July 2010) Uptodate
39 Questions?
Update on Oral Anticoagulation for Mechanical Heart Valves
Update on Oral Anticoagulation for Mechanical Heart Valves Douglas C. Anderson, Pharm.D., D.Ph. Professor and Chair Dept. of Pharmacy Practice Cedarville University School of Pharmacy OHIO SOCIETY OF HEALTH-SYSTEM
More informationSpotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France
Spotlight on valvular heart disease guidelines. Prosthetic heart valves. Bernard Iung Bichat Hospital, Paris Diderot University Paris, France Faculty disclosure First name - last name I disclose the following
More informationEchocardiographic Evaluation of Mitral Valve Prostheses
Echocardiographic Evaluation of Mitral Valve Prostheses Dennis A. Tighe, M.D., FACC, FACP, FASE Cardiovascular Medicine University of Massachusetts Medical School Worcester, MA www.asecho.org 1 Nishimura
More information2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD
2017 Cardiovascular Symposium CARDIAC SURGERY UPDATE: SMALLER INCISIONS AND LESS COUMADIN DAVID L. SAINT, MD David L Saint M.D. Tallahassee Memorial Hospital Southern Medical Group Division of Cardiothoracic
More informationFocused. se with 2008 F. lar Heart Diseas. date. ents With Valvul. Upd. gement of Patie. lines for Manag. HA 2006 Guidel ACC/AH. Fig.
ACC/AH HA 2006 Guidel nic severe AI (Fig. 4). ned by age, ay also be helpful nd echo. For AI, ollow up may be or MRI rather than mension; SD, end lines for Manag gement of Patie Upd ents With Valvul date
More informationTSDA Boot Camp September 13-16, Introduction to Aortic Valve Surgery. George L. Hicks, Jr., MD
TSDA Boot Camp September 13-16, 2018 Introduction to Aortic Valve Surgery George L. Hicks, Jr., MD Aortic Valve Pathology and Treatment Valvular Aortic Stenosis in Adults Average Course (Post mortem data)
More informationHeart Valves: Before and after surgery
Heart Valves: Before and after surgery Tim Sutton, Consultant Cardiologist Middlemore Hospital, Auckland Auckland Heart Group Indications for intervention in Valvular disease To prevent sudden death and
More informationA Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision
A Surgeon s Perspective Guidelines for the Management of Patients with Valvular Heart Disease Adapted from the 2006 ACC/AHA Guideline Revision Prof. Pino Fundarò, MD Niguarda Hospital Milan, Italy Introduction
More informationRESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES
e-issn:2322-0139 RESEARCH AND REVIEWS: JOURNAL OF PHARMACOLOGY AND TOXICOLOGICAL STUDIES Comparative Evaluation of Safety Outcomes of Different Prosthetic Valves in Indian Subjects. Kama Raval 1 *, Reena
More informationEcho Evaluation of a Mitral Valve Prostheses Sunday, February 14, :50 2:10 PM 20 min
2016 ASE State of the Art Echocardiography Course Tucson, AZ Echo Evaluation of a Mitral Valve Prostheses Sunday, February 14, 2016 1:50 2:10 PM 20 min 1 M U H A M E D S A R I Ć, M D, P H D D i r e c t
More informationClinical Practice Committee Anticoagulation Bridging Document
Original: 10/23/06 Last Updated: 10/30/07 Clinical Practice Committee Do patients on long term oral anticoagulant therapy who require short term interruption of warfarin for an elective invasive procedure
More informationAnticoagulation Therapy and Valve Surgery. Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon
Anticoagulation Therapy and Valve Surgery Dr Pau Kiew Kong Consultant Cardiothoracic Surgeon Outline of lecture 1. Type of Valve Surgery 2. Anticoagulation requirements 3. Mechanical (Metallic) prosthetic
More information42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim
42yr Old Male with Severe AR Mild LV dysfunction s/p TOF -AV Replacement(tissue valve) or AoV plasty- Kyung-Hwan Kim Current Guideline for AR s/p TOF Surgery is reasonable in adults with prior repair of
More informationW e have previously reported the results of a randomised
715 CARDIOVASCULAR MEDICINE Twenty year comparison of a mechanical heart valve with porcine bioprostheses H Oxenham, P Bloomfield, D J Wheatley, R J Lee, J Cunningham, R J Prescott, H C Miller... See end
More informationManagement of Patients With Valvular Heart Disease. ACC/AHA Pocket Guidelines
ACC/AHA Pocket Guidelines Management of Patients With Valvular Heart Disease A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines July 2000 ACC/AHA
More informationTAVI and Valve Replacement Thromboprophylaxis. Warren Prokopiw Pharmacy Resident
TAVI and Valve Replacement Thromboprophylaxis Warren Prokopiw Pharmacy Resident 2011-2012 Case Mr MW 76 yo Admitted 14 May for worsening CHF PMH: Aortic Stenosis, CVD (CABG x4 1980, PCI x3 stent 2008)
More informationAsif Serajian DO FACC FSCAI
Anticoagulation and Antiplatelet update: A case based approach Asif Serajian DO FACC FSCAI No disclosures relevant to this talk Objectives 1. Discuss the indication for antiplatelet therapy for cardiac
More informationValvular heart disease (VHD) is present in 2.5% of the
2017 Focused Update for Management of Patients With Valvular Heart Disease: Summary of New Recommendations Richard Matiasz, MD; Vera H. Rigolin, MD Valvular heart disease (VHD) is present in 2.5% of the
More informationBiological or mechanical valve prosthesis?
XXIX Giornate Cardiologiche Torinesi ADVANCES IN CARDIAC ARRHYTHMIAS AND GREAT INNOVATIONS IN CARDIOLOGY Turin, October 27-28, 2017 Centro Congressi Unione Industriale WHAT HAS CHANGED IN CARDIAC SURGERY?
More informationManagement of Valvular Heart Disease. Management of Valvular Heart Disease
Management of Valvular Heart Disease The Task Force on the Management of Valvular Heart Disease (Eur Heart J 2007;28:230-68) Chairperson Task Force Members Alec Vahanian, Paris (France) Task Force Members
More informationProsthesis-Patient Mismatch or Prosthetic Valve Stenosis?
EuroValves 2015, Nice Prosthesis-Patient Mismatch or Prosthetic Valve Stenosis? Philippe Pibarot, DVM, PhD, FACC, FAHA, FASE FESC Canada Research Chair in Valvular Heart Diseases Université LAVAL Disclosure
More informationHemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves
Hemodynamics Benefit of Supra-Annular Design in Failed Bio-Prosthetic Valves Speaker's name: I have the following potential conflicts of interest to report: Proctorship for Medtronic Agenda Failure modes
More informationValvular Heart Disease
Valvular Heart Disease B K Singh, MD, FACC Disclosures: None 1 CARDIAC CYCLE S2 S2=A2P2 S1=M1T1 S4 S1 S3 2 JVP Carotid S1 Slitting of S2 S3 S4 Ejection click Opening snap Dynamic Auscultation What is the
More informationA pregnant patient with a prosthetic valve Giacomo Boccuzzi, MD, FESC
A pregnant patient with a prosthetic valve Giacomo Boccuzzi, MD, FESC Department of Invasive Cardiology, Ospedale San Giovanni Bosco, Turin, Italy *C.V. was born the 24th May 1980 Rheumatic fever during
More informationShould We Reconsider using Anticoagulation for Biological Tissue Valves
Should We Reconsider using Anticoagulation for Biological Tissue Valves No Disclosures Disclosures Watching grass grow Complete with audio 1 hour 8 minutes 9884 views Subclinical Leaflet Thrombosis in
More informationHani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz
Hani K. Najm MD, Msc, FRCSC FACC, FESC President Saudi Society for Cardiac Surgeons Associate Professor of Cardiothoracic Surgery King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia Decision process for
More informationESC/EACTS Guidelines for the Management of Valvular Heart Disease
ES/EATS Guidelines for the Management of Valvular Heart Disease European Journal of ardio-thoracic Surgery 2012 - Why do we need new guidelines on the management of valvular disease? New evidence has been
More informationIndication, Timing, Assessment and Update on TAVI
Indication, Timing, Assessment and Update on TAVI Swedish Heart and Vascular Institute Ming Zhang MD PhD Interventional Cardiology Structure Heart Disease Conflict of Interest None Starr- Edwards Mechanical
More informationAntithrombotic therapy for patients with congenital heart disease. George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki
Antithrombotic therapy for patients with congenital heart disease George Giannakoulas, MD, PhD AHEPA University Hospital Thessaloniki Disclosures Educational fees from Astra Zeneca, GSK Research fees from
More informationPROSTHETIC. V PROSTHETIC.V
PROSTHETIC. V PROSTHETIC.V VALVE TYPE The valve types now implanted include: 1-bileaflet and tilting disc mechanical valves, 2-stented porcine and pericardial xenografts, 3-stentless porcine xenografts,
More informationProsthetic valve dysfunction: stenosis or regurgitation
Prosthetic valve dysfunction: stenosis or regurgitation Jean G. Dumesnil MD, FRCP(C), FACC, FASE(Hon) Quebec Heart and Lung Institute, Québec, Québec No disclosures Possible Causes of High Gradients in
More informationSlide 1: Perioperative Management of Anticoagulation
Perioperative Management of Anticoagulation by Steven L. Cohn, MD, FACP Director, Medical Consultation Service, Kings County Hospital Center, Clinical Professor of Medicine, SUNY Downstate, Brooklyn, NY
More informationPrimary Care practice clinics within the Edmonton Southside Primary Care Network.
INR Monitoring and Warfarin Dose Adjustment Last Review: November 2016 Intervention(s) and/or Procedure: Registered Nurses (RNs) adjust warfarin dosage according to individual patient International Normalized
More informationAdult Cardiac Surgery
Adult Cardiac Surgery Mahmoud ABU-ABEELEH Associate Professor Department of Surgery Division of Cardiothoracic Surgery School of Medicine University Of Jordan Adult Cardiac Surgery: Ischemic Heart Disease
More informationIntensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA (GELIA 5)
European Heart Journal Supplements () 3 (Supplement Q), Q39 Q43 Intensity of oral anticoagulation after implantation of St. Jude Medical mitral or multiple valve replacement: lessons learned from GELIA
More informationCarpentier-Edwards Pericardial Valve in the Aortic Position: 25-Years Experience
SURGERY: The Annals of Thoracic Surgery CME Program is located online at http://www.annalsthoracicsurgery.org/cme/ home. To take the CME activity related to this article, you must have either an STS member
More informationHoly Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH
Holy Crap! Why is a Cardiologist Speaking at a GI Meeting? Jonathan A. Rapp, MD, FACC, FSCAI Cardiologist, Mercy Heart Institute Cincinnati, OH Goals and Objectives Discuss cardiac considerations for patients
More informationAntithrombotic therapy in valvular heart disease and artificial valves
Available online at www.sciencedirect.com journal homepage: www.elsevier.com/locate/crvasa Review Article Special issue: Thrombosis Antithrombotic therapy in valvular heart disease and artificial valves
More informationAniticoagulation in Patients Following Prosthetic Heart Valve Replacement
Original Article Aniticoagulation in Patients Following Prosthetic Heart Valve Replacement Raja Parvez Akhtar, FRCS, 1 Abdul Rehman Abid, FCPS, 2 Hasnain Zafar, MBBS, 1 and Jawad Sajid Khan, FRCS 1 Purpose:
More informationClinical Practice Guideline for Anticoagulation Management
Clinical Practice Guideline for Anticoagulation Management This guideline is to inform practitioners of the Standard of Care for providing safe and effective anticoagulation management for ambulatory patients.
More informationWarfarin in Adults : Guidelines for the use of. These guidelines apply to all patients commenced or continuing on warfarin
Warfarin in Adults : Guidelines for the use of Document Type: Clinical Guideline Clinical Lead: Ian Neilly Author/s: Ian Neilly/Paul Barbieri Directorate: Haematology Approved by Haematology Specialty
More informationHani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia.
Hani K. Najm MD, Msc, FRCSC, FRCS (Glasgow), FACC, FESC President of Saudi Heart Association King Abdulaziz Cardiac Centre Riyadh, Saudi Arabia. Decision process for Management of any valve Timing Feasibility
More informationCase Report. Ilias K Karabinos, MD, FESC, 1 Athanasios Kranidis, MD, FESC, 2 Vassilios N Spanos, MD 1
HOSPITAL CHRONICLES 2010, 5(1): 1 5 Case Report Acute Myocardial Infarction Presumably Embolic, in a Patient With a Mechanical Aortic Valve: a Rare Cause of Non-Atherosclerotic Coronary Artery Occlusion
More informationClinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!!
Clinicians and Facilities: RESOURCES WHEN CARING FOR WOMEN WITH ADULT CONGENITAL HEART DISEASE OR OTHER FORMS OF CARDIOVASCULAR DISEASE!! Abha'Khandelwal,'MD,'MS' 'Stanford'University'School'of'Medicine'
More informationGestione peri-operatoria del paziente in terapia con antagonisti della vitamina K. B. Cosmi
Gestione peri-operatoria del paziente in terapia con antagonisti della vitamina K B. Cosmi Department of Angiology and Blood Coagulation S. Orsola-Malpighi University Hospital Bologna, Italy Overview Background
More informationTreatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques
Treatment of Bio-Prosthetic Valve Deterioration Using Transcatheter Techniques Pablo Codner, Abid Assali, Hanna Vaknin-Assa, Katia Orvin, Ram Sharony, Leor Perl, Gabriel Greenberg, Marina Kupershmidt,
More informationA Practical Approach to Prosthetic Valves
A Practical Approach to Prosthetic Valves Bonita Anderson DMU (Cardiac), MApplSc (Med Ultrasound), ACS, AMS, FASE https://doi.org/10.1161/circulationaha.108.778886 Disclosures None 1 Know the Product Know
More informationExpanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated?
Expanding Relevance of Aortic Valve Repair Is Earlier Operation Indicated? RM Suri, V Sharma, JA Dearani, HM Burkhart, RC Daly, LD Joyce, HV Schaff Division of Cardiovascular Surgery, Mayo Clinic, Rochester,
More informationPrognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding hazards
European Heart Journal Supplements (1) 3 (Supplement Q), Q27 Q32 Prognosis after aortic valve replacement with St. Jude Medical bileaflet prostheses: impact on outcome of varying thromboembolic and bleeding
More informationLong-term bleeding events after mechanical aortic valve replacement in patients under the age of 60
Neth Heart J (2015) 23:111 115 DOI 10.1007/s12471-014-0626-9 ORIGINAL ARTICLE Long-term bleeding events after mechanical aortic valve replacement in patients under the age of 60 B. M. Swinkels & B. A.
More informationMitral valve replacement in patients under 65 years of age: mechanical or biological valves?
REVIEW C URRENT OPINION Mitral valve replacement in patients under 65 years of age: mechanical or biological valves? David C. Reineke, Paul Philipp Heinisch, Bernhard Winkler, Lars Englberger, and Thierry
More informationEVERYTHING ABOUT MECHANICAL VALVES HAS CHANGED
EVERYTHING ABOUT MECHANICAL VALVES HAS CHANGED 106180.001 CryoLife - New Brochure FIN.indd 1 06/10/2016 14:08 Why use another mechanical valve when 1 2 3 No other mechanical valve has: 1 90 leaflets: 1
More information16 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900
CLINICAL COMMUNIQUé 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 69 The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 69, was introduced into clinical
More information2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease
2017 Update to the AHA/ACC Guideline for Management of Mitral Valve Disease Patrick T. O Gara, MD BWH Heart and Vascular Center Professor of Medicine, Harvard Medical School Disclosures NHLBI CTSN Co-chair
More informationCoreValve in a Degenerative Surgical Valve
CoreValve in a Degenerative Surgical Valve Ran Kornowski, MD, FESC, FACC Chairman Department of Cardiology Rabin Medical Center, Petach Tikva, Israel Disclosure Statement of Financial Interest I, Ran Kornowski,
More informationTAVR for Valve-In-Valve. Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology
TAVR for Valve-In-Valve Brian O Neill Assistant Professor of Medicine Department of Medicine, Section of Cardiology Temple Hearth and Vascular Institute Disclosures: Consultant: Cardiac Assist TAVR for
More informationThe introduction of valve replacement surgery in the early
Valvular Heart Disease: Changing Concepts in Disease Management Prosthetic Heart Valves Selection of the Optimal Prosthesis and Long-Term Management Philippe Pibarot, DVM, PhD; Jean G. Dumesnil, MD, FRCP(C)
More informationSubclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study
Subclinical leaflet thrombosis in surgical and transcatheter bioprosthetic aortic valves: an observational study Meagan Sullivan, PharmD PGY2 Cardiology Pharmacy Resident University of Chicago Medicine
More informationDepartment of Cardiac Surgery, Trousseau University Hospital, Tours, France
Risk Factors for Valve-Related Complications after Mechanical Heart Valve Replacement in 505 Patients with Long-Term Follow Up Thierry Bourguignon, Eric Bergöend, Alain Mirza, Grégoire Ayegnon, Paul Neville,
More informationTAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair?
TAVI- Is Stroke Risk the Achilles Heel of Percutaneous Aortic Valve Repair? Elaine E. Tseng, MD and Marlene Grenon, MD Department of Surgery Divisions of Adult Cardiothoracic and Vascular and Endovascular
More informationAlthough mitral valve replacement (MVR) is no longer the surgical
Surgery for Acquired Cardiovascular Disease Ruel et al Late incidence and predictors of persistent or recurrent heart failure in patients with mitral prosthetic valves Marc Ruel, MD, MPH a,b Fraser D.
More informationBleeding Management Strategies. Aiming for the best Outcomes August 27, Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM
Bleeding Management Strategies Aiming for the best Outcomes August 27, 2016 Amit Gupta, MD FACC FSCAI Interventional Cardiologist CANM Learning Objectives Review the use of anti-coagulants in patients
More informationEchocardiographic Evaluation of Aortic Valve Prosthesis
Echocardiographic Evaluation of Aortic Valve Prosthesis Amr E Abbas, MD, FACC, FASE, FSCAI, FSVM, RPVI Co-Director, Echocardiography, Director, Interventional Cardiology Research, Beaumont Health System
More informationmm Porcine valve Patient had requested
Mrs CY Age 77 History 2000:Age 60: MVR 27mm St Jude Valve (severe MR) 2015:Age 75: Paravalvular mitral leak, haemolytic anaemia, tricuspid incompetence. 27mm Porcine valve and 29mm Duran ring tricuspid
More informationIatrogenic pathology of the heart:
Iatrogenic pathology of the heart: Complications of mitral valve plasty and replacement Patrick Bruneval D pt of Pathology Hôpital Européen Georges Pompidou Enterprise Interest None Mitral valve surgery
More informationLate failure of transcatheter heart valves: An open question
Late failure of transcatheter heart valves: An open question A comparison with surgically implanted bioprosthetic heart valves. A. Rashid The Cardiothoracic Centre Liverpool, UK. Conflict of Interest Statement
More informationTitle of image and video article Sub-Acute Leaflet Thrombosis: A Reversible Cause of Aortic Stenosis
Page 1 of 5 Title of image and video article Sub-Acute Leaflet Thrombosis: A Reversible Cause of Aortic Stenosis Authors Athina Chasapi, Adam Hobbs, Theodore Velissaris & Benoy N Shah. Wessex Cardiac &
More informationCritical Care in Obstetrics: An Innovative and Integrated Model for Learning the Essentials
Critical Care in Obstetrics: An Innovative and Integrated Model for Learning the Essentials Pregnancy and Congenital Heart Disease Case Review Heidi M. Connolly, M.D. Professor of Medicine Chair for Education
More informationDespite improvements in valve design, stroke remains a serious
Surgery for Acquired Cardiovascular Disease Bando et al Early and late stroke after mitral valve replacement with a mechanical prosthesis: Risk factor analysis of a 24-year experience Ko Bando, MD a Junjiro
More informationSREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY THIRUVANANTHAPURAM, KERALA, INDIA
SREE CHITRA TIRUNAL INSTITUTE FOR MEDICAL SCIENCES AND TECHNOLOGY THIRUVANANTHAPURAM, KERALA, INDIA - 695011 St. Jude Medical versus TTK Chitra mechanical heart valves at aortic/mitral postion Comparison
More informationManuel Castella MD PhD Hospital Clínic, University of
Manuel Castella MD PhD Hospital Clínic, University of Barcelona mcaste@clinic.ub.es @mcastellamd www.escardio.org/guidelines European Heart Journal - doi:10.1093/eurheartj/ehw210 Providing integrated care
More informationMechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute
Mechanical vs. Bioprosthetic Aortic Valve Replacement: Time to Reconsider? Christian Shults, MD Cardiac Surgeon, Medstar Heart and Vascular Institute Assistant Professor, Georgetown School of Medicine
More informationIs Stroke Frequency Declining?
Is Stroke Frequency Declining? Etiologic Factors Clinical, Anatomic, Technique-related, and Device-specific Samir Kapadia, MD Professor of Medicine Section head, Interventional Cardiology Director, Cardiac
More informationDirect Oral Anticoagulant Use in Valvular Atrial Fibrillation
Direct Oral Anticoagulant Use in Valvular Atrial Fibrillation September 14, 2018 Nina Maguire, PharmD PGY1 Pharmacy Resident Seton Healthcare Family Christina.maguire@ascension.org ASCENSION TEXAS Direct
More informationOutcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison
Outcome of Next-Generation Transcatheter Valves in Small Aortic Annuli: A Multicenter Propensity-Matched Comparison Mauri, V. et al.: Circ Cardiovasc Interv. 2017;10:e005013 All trademarks are the property
More informationI will not discuss off label use or investigational use in my presentation. Consultant for: Astra Zeneca, BayerHealthcare, Boehringer Ingelheim,
I will not discuss off label use or investigational use in my presentation. Consultant for: Astra Zeneca, BayerHealthcare, Boehringer Ingelheim, Daiichi- Sankyo, Lilly, Sanofi-Aventis Honoraria from: Astra
More informationACCP Cardiology PRN Journal Club
ACCP Cardiology PRN Journal Club 1 Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease Cody A. Carson, PharmD, BCPS PGY2 Cardiology Pharmacy Resident
More informationAntithrombotic. DAPT or OAC?
Antithrombotic treatment after TAVI: DAPT or OAC? Striking the right balance. Pascal Vranckx MD, PhD. Hartcentrum Hasselt, Belgium. Disclosure of Interest Pascal Vranckx has the following potential conflicts
More informationDisclosures. Overview. Have you ever. The Perioperative Management of Anticoagulants. No financial conflicts of interest to disclose
Disclosures No financial conflicts of interest to disclose The Perioperative Management of Anticoagulants Margaret C. Fang, MD, MPH Associate Professor of Medicine UCSF Division of Hospital Medicine Medical
More informationΧειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας
Χειρουργική Αντιμετώπιση της Ανεπάρκειας της Μιτροειδούς Βαλβίδας Dr Χρήστος ΑΛΕΞΙΟΥ MD, PhD, FRCS(Glasgow), FRCS(CTh), CCST(UK) Consultant Cardiothoracic Surgeon Normal Mitral Valve Function Mitral Regurgitation
More informationThe ATS Medical Open Pivot heart valve (ATS Medical, 10-Year Experience With the ATS Mechanical Valve in the Mitral Position
10-Year Experience With the ATS Mechanical Valve in the Mitral Position Constantin Stefanidis, MD, Albert M. Nana, MD, Didier De Cannière, MD, PhD, Martine Antoine, MD, Jean-Luc Jansens, MD, Chi-Hoang
More informationHeart valve replacement with the Bjork-Shiley and St Jude Medical prostheses: A randomized comparison in 178 patients
European Heart Journal (1990) 11, 583-591 Heart valve replacement with the Bjork-Shiley and St Jude Medical prostheses: A randomized comparison in 178 patients S. VOGT, A. HOFFMANN, J. ROTH, P. DUBACH,
More informationTranscatheter Aortic Valve Replacement
Transcatheter Aortic Valve Replacement Jesse Jorgensen, MD Medical Director, Cardiac Catheterization Laboratory Greenville Health System Greenville, South Carolina, USA January 30, 2016 Aortic Stenosis
More informationAnticoagulation Overview Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita
Anticoagulation Overview 2018 Jed Delmore, MD, FACS, FACOG Professor Obstetrics and Gynecology University of Kansas School of Medicine, Wichita The ideal lecture is like a miniskirt. Short enough to get
More informationSurgical Indications of Infective Endocarditis in Children
2016 Annual Spring Scientific Conference of the KSC April 15-16, 2016 Surgical Indications of Infective Endocarditis in Children Cheul Lee, MD Pediatric and Congenital Cardiac Surgery Seoul St. Mary s
More informationPerioperative Management. Perioperative Management of Cardiovascular Medications
of Cardiovascular Medications Carmine D Amico, D.O. Overview Learning objectives Beta-blockers Statins Alpha-2 agonists Calcium channel blockers ACE inhibitors and ARB s Anticoagulants Antiplatelet agents
More informationValve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal
Valve Disease in Patients With Heart Failure TAVI or Surgery? Miguel Sousa Uva Hospital Cruz Vermelha Lisbon, Portugal I have nothing to disclose. Wide Spectrum Stable vs Decompensated NYHA II IV? Ejection
More informationCLINICAL COMMUNIQUE 16 YEAR RESULTS
CLINICAL COMMUNIQUE 6 YEAR RESULTS Carpentier-Edwards PERIMOUNT Mitral Pericardial Bioprosthesis, Model 6900 Introduction The Carpentier-Edwards PERIMOUNT Mitral Pericardial Valve, Model 6900, was introduced
More informationLong-Term Results With the Medtronic-Hall Valvular Prosthesis
Long-Term Results With the Medtronic-Hall Valvular Prosthesis Cary W. Akins, MD Cardiac Surgical Unit, Massachusetts General Hospital, Boston, Massachusetts Background. Although more than 170,000 Medtronic-
More informationWARFARIN: PERI OPERATIVE MANAGEMENT
WARFARIN: PERI OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin treated patients who require an elective or urgent surgery/procedure. To provide an approach
More informationChoice of Prosthetic Heart Valve in Adults
Journal of the American College of Cardiology Vol. 55, No. 22, 2010 2010 by the American College of Cardiology Foundation ISSN 0735-1097/$36.00 Published by Elsevier Inc. doi:10.1016/j.jacc.2009.10.085
More informationUpdates in Stroke Management. Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy
Updates in Stroke Management Jessica A Starr, PharmD, FCCP, BCPS Associate Clinical Professor Auburn University Harrison School of Pharmacy Disclosure I have no actual or potential conflict of interest
More information25 different brand names >44 different models Sizes mm
Types of Prosthetic Valves BIOLOGIC STENTED Porcine xenograft Pericardial xenograft STENTLESS Porcine xenograft Pericardial xenograft Homograft (allograft) Autograft PERCUTANEOUS MECHANICAL Bileaflet Single
More information30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the FORWARD Study
30-Day Outcomes Following Implantation of a Repositionable Self-Expanding Aortic Bioprosthesis: First Report From the Study Stephan Windecker Department of Cardiology Bern University Hospital - INSELSPITAL
More informationTAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central
TAVR-Update Andrzej Boguszewski MD, FACC, FSCAI Vice Chairman, Cardiology Mid-Michigan Health Associate Professor Michigan State University, Central Michigan University 1 Disclosure Chiesi Pharma- Consultant
More informationSign up to receive ATOTW weekly -
ANTICOAGULATION & INTRACRANIAL BLEEDS - MANAGEMENT OF THE ANTICOAGULATED PATIENT PRESENTING WITH INTRACRANIAL HAEMORRHAGE ANAESTHESIA TUTORIAL OF THE WEEK 82 12 th January 2008 Rebecca Appelboam, Exeter,
More informationLong-term results (22 years) of the Ross Operation a single institutional experience
Long-term results (22 years) of the Ross Operation a single institutional experience Authors: Costa FDA, Schnorr GM, Veloso M,Calixto A, Colatusso D, Balbi EM, Torres R, Ferreira ADA, Colatusso C Department
More informationDISCLOSURE. Mitral ViV: why? Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? UW Medicine NONE.
Mitral Valve- in- Valve: Procedural Image Guidance with TEE, a Must Have or Nice to Have? G. Burkhard Mackensen, MD, PhD, FASE Professor & Chief, Division of Cardiothoracic Anesthesia, Department of Anesthesiology
More informationAfib, Stroke, and DOAC. Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS
Afib, Stroke, and DOAC Albert Luo, MD. Cardiology Lindsey Frischmann, DO. Neurology Xiao Cai, MD. HBS Disclosure of Relevant Financial Relationships I have no relevant financial relationships with commercial
More informationWARFARIN: PERI-OPERATIVE MANAGEMENT
WARFARIN: PERI-OPERATIVE MANAGEMENT OBJECTIVE: To provide an approach to the perioperative management of warfarin-treated patients who require an elective or urgent surgery/procedure. To provide an approach
More information